A detailed history of Synovus Financial Corp transactions in Veracyte, Inc. stock. As of the latest transaction made, Synovus Financial Corp holds 22,865 shares of VCYT stock, worth $846,919. This represents 0.01% of its overall portfolio holdings.

Number of Shares
22,865
Previous 19,670 16.24%
Holding current value
$846,919
Previous $426,000 82.63%
% of portfolio
0.01%
Previous 0.01%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$21.0 - $35.25 $67,095 - $112,623
3,195 Added 16.24%
22,865 $778,000
Q2 2024

Aug 13, 2024

BUY
$18.86 - $23.55 $1,263 - $1,577
67 Added 0.34%
19,670 $426,000
Q1 2024

May 14, 2024

BUY
$21.0 - $29.1 $84,105 - $116,545
4,005 Added 25.68%
19,603 $434,000
Q3 2023

Nov 13, 2023

BUY
$22.33 - $29.92 $28,560 - $38,267
1,279 Added 8.93%
15,598 $348,000
Q2 2023

Aug 08, 2023

SELL
$20.96 - $26.99 $11,737 - $15,114
-560 Reduced 3.76%
14,319 $364,000
Q1 2023

May 11, 2023

SELL
$20.58 - $27.89 $126,114 - $170,909
-6,128 Reduced 29.17%
14,879 $331,000
Q4 2022

Feb 06, 2023

BUY
$15.31 - $29.94 $11,972 - $23,413
782 Added 3.87%
21,007 $498,000
Q3 2022

Oct 27, 2022

BUY
$16.58 - $27.9 $13,396 - $22,543
808 Added 4.16%
20,225 $334,000
Q2 2022

Aug 10, 2022

BUY
$15.45 - $29.52 $9,439 - $18,036
611 Added 3.25%
19,417 $382,000
Q1 2022

May 12, 2022

BUY
$21.94 - $42.51 $163,101 - $316,019
7,434 Added 65.37%
18,806 $515,000
Q4 2021

Feb 14, 2022

BUY
$36.09 - $53.79 $64,745 - $96,499
1,794 Added 18.73%
11,372 $464,000
Q3 2021

Nov 08, 2021

BUY
$35.62 - $52.97 $77,259 - $114,891
2,169 Added 29.28%
9,578 $442,000
Q2 2021

Aug 11, 2021

BUY
$32.94 - $56.62 $80,340 - $138,096
2,439 Added 49.07%
7,409 $305,000
Q1 2021

May 11, 2021

BUY
$44.47 - $81.38 $221,015 - $404,458
4,970 New
4,970 $264,000

Others Institutions Holding VCYT

About VERACYTE, INC.


  • Ticker VCYT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 71,575,904
  • Market Cap $2.65B
  • Description
  • Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer ...
More about VCYT
Track This Portfolio

Track Synovus Financial Corp Portfolio

Follow Synovus Financial Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Synovus Financial Corp, based on Form 13F filings with the SEC.

News

Stay updated on Synovus Financial Corp with notifications on news.